A Phase 1 Single and Multiple Ascending Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZT-01 in Healthy Volunteers and in Patients with Type 1 Diabetes (T1D)
Latest Information Update: 20 Sep 2022
At a glance
- Drugs ZT-01 (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions
- Sponsors Zucara Therapeutics
- 19 Sep 2022 Results published into a Zucara Therapeutics Media Release.
- 26 May 2021 Results presented in a Zucara Therapeutics media release.
- 26 May 2021 Status changed from recruiting to completed, according to a Zucara Therapeutics media release.